Roivant Sciences (ROIV) – Analysts’ Weekly Ratings Updates

by · The Cerbat Gem

A number of firms have modified their ratings and price targets on shares of Roivant Sciences (NASDAQ: ROIV) recently:

  • 12/18/2025 – Roivant Sciences had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $28.00 price target on the stock.
  • 12/15/2025 – Roivant Sciences had its price target raised by analysts at Leerink Partners from $29.00 to $32.00. They now have an “outperform” rating on the stock.
  • 12/15/2025 – Roivant Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a “buy” rating on the stock.
  • 12/12/2025 – Roivant Sciences had its price target raised by analysts at HC Wainwright from $23.00 to $26.00. They now have a “buy” rating on the stock.
  • 11/16/2025 – Roivant Sciences was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating.
  • 11/14/2025 – Roivant Sciences had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $25.00 price target on the stock.
  • 11/11/2025 – Roivant Sciences had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $29.00 price target on the stock.
  • 11/11/2025 – Roivant Sciences had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a “buy” rating on the stock.

Insider Activity

In other Roivant Sciences news, Director Daniel Allen Gold sold 777,332 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $23.07, for a total value of $17,933,049.24. Following the sale, the director owned 16,353,113 shares of the company’s stock, valued at approximately $377,266,316.91. This trade represents a 4.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Richard Pulik sold 406,731 shares of the company’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total value of $9,122,976.33. Following the sale, the chief financial officer owned 239,413 shares of the company’s stock, valued at approximately $5,370,033.59. This represents a 62.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 12,443,733 shares of company stock valued at $260,403,796. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

Featured Articles